ATT-377 has a significant preventative impact on appetite and weight
Immediate impact on Appetite
Within the first week of treatment, patients have significantly better (p<.001) appetites than on methylphenidate alone. This includes a improvement on appetite at lunchtime.
Weight was significantly improved after 12 weeks of treatment
At study completion, weight increased significantly more (p<.0001) with ATT-377 than in the control arm. This robust response was also seen when adjusted for age and gender using the CDC growth curves. 12 weeks is longer than a typical ADHD study period indicating a enduring effect of treatment.
Patients taking stimulant therapy for the first time were protected from weight loss
Subgroup analysis shows that patients who had never taken therapy for ADHD, were protected by ATT-377 vs. those in the control group.
Fully Treat ADHD without use of "DRUG Holidays" to manage adverse effects
Combination treatment does not negatively impact attentiveness
The combination pulsatile delivery of cyproheptadine during the daytime did not decrease the effectiveness of methylphenidate on ADHD.
Methylphenidate doses may be increased as required
Methylphenidate doses ranged from 18mg to 72mg in the clinical trial.